Forest hit by US product delays
This article was originally published in Scrip
Forest Laboratories has suffered setbacks to its pipeline after a meeting with the US FDA prompted it to postpone its NDA for the COPD treatment aclidinium bromide, which is being developed under a partnership with Almirall. On the same day, the company announced it was pushing back the US launch of its SNRI Savella (milnacipran HCl) for fibromyalgia while it seeks approval for a minor change.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.